Skip to main content

News

News

The group has been awarded an NIHR i4i Product Development for a 3 year project

The project is titled, 'In-vitro diagnostic device development and validation, enabling point-of-care therapeutic drug monitoring for dose optimisation of anthracycline chemotherapy in a paediatric cancer setting'.

The £977,609 grant, in collaboration with colleagues at UCL, will be used to develop a novel device to measure drug levels in patients in order to control drug exposure. The aim is to avoid unnecessary side-effects for a group of drugs widely used in childhood cancer treatment.

Innovate UK award

Phil Berry was awarded £75k from Innovate UK in September 2020, for a 3 year project led by Phil Berry entitled: Establishing a translational leader in precision medicine through knowledge transfer to develop point-of-care drug monitoring technologies.

Cancer Research UK Funding award

The first platform study investigating the safety of DNA Damage response inhibitors in combination with curative intent doses of radiotherapy in stage II and III lung Cancer CONCORDE was funded by Cancer Research UK in July 2019 and will shortly announce its 1st pharmaceutical partner. It is led by Dr Alastair Greystoke and key biomarkers of cardiac toxicity will be analysed within the group.